These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 19706888)
1. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888 [TBL] [Abstract][Full Text] [Related]
2. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF Front Immunol; 2018; 9():3016. PubMed ID: 30619360 [TBL] [Abstract][Full Text] [Related]
3. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170 [TBL] [Abstract][Full Text] [Related]
4. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Griffioen M; van der Meijden ED; Slager EH; Honders MW; Rutten CE; van Luxemburg-Heijs SA; von dem Borne PA; van Rood JJ; Willemze R; Falkenburg JH Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3837-42. PubMed ID: 18316730 [TBL] [Abstract][Full Text] [Related]
5. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532 [TBL] [Abstract][Full Text] [Related]
6. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570 [TBL] [Abstract][Full Text] [Related]
7. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
8. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation. Kremer AN; van der Griendt JC; van der Meijden ED; Honders MW; Ayoglu B; Schwenk JM; Nilsson P; Falkenburg JH; Griffioen M Haematologica; 2014 Feb; 99(2):365-9. PubMed ID: 24097630 [TBL] [Abstract][Full Text] [Related]
9. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction. van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556 [TBL] [Abstract][Full Text] [Related]
10. Minor histocompatibility antigens in human stem cell transplantation. Falkenburg JH; van de Corput L; Marijt EW; Willemze R Exp Hematol; 2003 Sep; 31(9):743-51. PubMed ID: 12962719 [TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation. Fuchs KJ; Falkenburg JHF; Griffioen M Best Pract Res Clin Haematol; 2024 Jun; 37(2):101555. PubMed ID: 39098803 [TBL] [Abstract][Full Text] [Related]
12. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962 [TBL] [Abstract][Full Text] [Related]
13. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM Front Immunol; 2020; 11():1804. PubMed ID: 32973756 [TBL] [Abstract][Full Text] [Related]
14. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens. Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M Front Immunol; 2020; 11():659. PubMed ID: 32362897 [TBL] [Abstract][Full Text] [Related]
15. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. Milosevic S; Bachnick B; Karim K; Bornkamm GW; Witter K; Gerbitz A; Mautner J; Behrends U Transplantation; 2010 Nov; 90(9):1030-5. PubMed ID: 20802400 [TBL] [Abstract][Full Text] [Related]
16. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967 [TBL] [Abstract][Full Text] [Related]
18. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765 [TBL] [Abstract][Full Text] [Related]
19. Identification of novel minor histocompatibility antigens responsible for graft-versus-leukemia (GVL) effect on chronic myeloid leukemia: usefulness of determining the clonotype of T cells associated with GVL effect after donor leukocyte infusion. Nakao S Int J Hematol; 2002 Aug; 76 Suppl 1():274-6. PubMed ID: 12430863 [TBL] [Abstract][Full Text] [Related]
20. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]